Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves First RSV vaccine for adults under 60
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus.
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
NEW YORK, NY, USA I2, 2024 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO®
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
6h
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
8h
on MSN
Second dose of this year's COVID vaccine recommended for some people age 65 and up
The CDC recommends that immunocompromised people age 65 and older should get a second dose of the 2024-2025 COVID vaccine.
9h
Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...
The Citizen
3d
After investigation, Covid vaccine mandates just look bad, even corrupt
In last week’s column, I told you how the 2024 General Election (early voting has started) could lead to healthier, smarter, and longer lives for all of us (see: ...
11d
Man says he has been 'left to rot' after Covid vaccine
Mr Lowe said that while he was not opposed to vaccines, his life had been destroyed. The Public Health Agency (PHA) said the ...
2d
Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
2d
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...
14h
Stanley Laman Group Ltd. Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)
Stanley Laman Group Ltd. cut its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.2% in the 3rd quarter, Holdings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback